{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:45:33Z","timestamp":1776743133108,"version":"3.51.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001721","name":"University of Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:29:08Z","timestamp":1766125748000},"page":"e502-e510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8902-4162","authenticated-orcid":false,"given":"Koen M.","family":"Klomberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Gelderloos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde A.M.","family":"Kooistra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerwin A.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirian","family":"Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-8001","authenticated-orcid":false,"given":"Wilfried W.H.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2025.12.007_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.12.007_bib0002","unstructured":"Brink M., Korf-van Vliet C.H., Plaisier M., et al. Het multipel myeloom in Nederland, 2014-2017. Landelijk rapport van het hemato-oncologie register van de Nederlandse Kankerregistratie. The Netherlands: integraal kanker centrum Nederland. 2020. vol. 33. Report no. 3. https:\/\/iknl.nl\/getmedia\/c5458b99-3920-4c16-a750-62cdd5f5f55f\/IKNL-Landelijke-rapportage-2014-2017-MM.pdf. Accessed June 1, 2025."},{"key":"10.1016\/j.clml.2025.12.007_bib0003","doi-asserted-by":"crossref","unstructured":"Moreau P, Hulin C, Perrot A et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 2024. doi: 10.1016\/S1470-2045(24)00282-1","DOI":"10.1016\/S1470-2045(24)00282-1"},{"key":"10.1016\/j.clml.2025.12.007_bib0004","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Sborov DW, Laubach J et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023; 10(10): e825-37. doi: 10.1016\/S2352-3026(23)00217-X","DOI":"10.1016\/S2352-3026(23)00217-X"},{"issue":"4","key":"10.1016\/j.clml.2025.12.007_bib0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2025.12.007_bib0006","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.12.007_bib0007","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.12.007_bib0008","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.12.007_bib0009","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.12.007_bib0010","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.12.007_bib0011","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1182\/blood.V128.22.3460.3460","article-title":"Favourable outcome of elderly patients with multiple myeloma treated with tandem melphalan 100 high-dose therapy, autologous stem cell transplantation and novel agents - a single center experience","volume":"128","author":"Neukirchen","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.12.007_bib0012","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3324\/haematol.2013.096149","article-title":"Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers","volume":"99","author":"Mohty","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.12.007_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age \u2265 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.007_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ejh.13690","article-title":"Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma","volume":"107","author":"Straka","year":"2021","journal-title":"Eur J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2025.12.007_bib0015","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.clml.2025.12.007_bib0016","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Moreau","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.007_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.12.007_bib0018","unstructured":"IKNL. Netherlands Cancer Registry (NCR): 2024 Available at: https:\/\/iknl.nl\/en\/ncr Accessed October 24, 2024."},{"issue":"1","key":"10.1016\/j.clml.2025.12.007_bib0019","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12967-019-2122-x","article-title":"The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective","volume":"17","author":"Sidorenkov","year":"2019","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.clml.2025.12.007_bib0020","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.007_bib0021","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.clml.2025.12.007_bib0022","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.12.007_bib0023","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of Daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.12.007_bib0024","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.12.007_bib0025","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.clml.2025.12.007_bib0026","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.007_bib0027","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-023-00905-8","article-title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","volume":"13","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Suppl 6","key":"10.1016\/j.clml.2025.12.007_bib0028","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.htct.2023.07.012","article-title":"Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study","volume":"46","author":"Seehaus","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2025.12.007_bib0029","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-related quality of life after autologous stem cell transplantation for multiple myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.12.007_bib0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","article-title":"Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation","volume":"15","author":"Sherman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.12.007_bib0031","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/bmt.2010.304","article-title":"A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up","volume":"46","author":"Fr\u00f6din","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2025.12.007_bib0032","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/cncr.23299","article-title":"Symptom burden after autologous stem cell transplantation for multiple myeloma","volume":"112","author":"Campagnaro","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2025.12.007_bib0033","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.bmt.1705664","article-title":"Symptom burden in patients undergoing autologous stem-cell transplantation","volume":"39","author":"Anderson","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"11 Suppl","key":"10.1016\/j.clml.2025.12.007_bib0034","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/cncr.21488","article-title":"Adult cancer survivors: how are they faring?","volume":"104","author":"Baker","year":"2005","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.clml.2025.12.007_bib0035","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.12.007_bib0036","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.12.007_bib0037","first-page":"m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ (Clinical research ed.)"},{"issue":"4","key":"10.1016\/j.clml.2025.12.007_bib0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.12.007_bib0039","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2025.12.007_bib0040","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:16:30Z","timestamp":1776741390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025043022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025043022"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}